195 related articles for article (PubMed ID: 30393924)
1. Subgroups of IBS patients are characterized by specific, reproducible profiles of GI and non-GI symptoms and report differences in healthcare utilization: A population-based study.
Polster AV; Palsson OS; Törnblom H; Öhman L; Sperber AD; Whitehead WE; Simrén M
Neurogastroenterol Motil; 2019 Jan; 31(1):e13483. PubMed ID: 30393924
[TBL] [Abstract][Full Text] [Related]
2. Mixture model analysis identifies irritable bowel syndrome subgroups characterised by specific profiles of gastrointestinal, extraintestinal somatic and psychological symptoms.
Polster A; Van Oudenhove L; Jones M; Öhman L; Törnblom H; Simrén M
Aliment Pharmacol Ther; 2017 Sep; 46(5):529-539. PubMed ID: 28671338
[TBL] [Abstract][Full Text] [Related]
3. Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population.
Tornkvist NT; Aziz I; Whitehead WE; Sperber AD; Palsson OS; Hreinsson JP; Simrén M; Törnblom H
United European Gastroenterol J; 2021 Dec; 9(10):1178-1188. PubMed ID: 34599559
[TBL] [Abstract][Full Text] [Related]
4. A Novel Method to Classify and Subgroup Patients With IBS Based on Gastrointestinal Symptoms and Psychological Profiles.
Black CJ; Yiannakou Y; Guthrie EA; West R; Houghton LA; Ford AC
Am J Gastroenterol; 2021 Feb; 116(2):372-381. PubMed ID: 33110014
[TBL] [Abstract][Full Text] [Related]
5. The epidemiology of irritable bowel syndrome in Denmark. A population-based survey in adults ≤50 years of age.
Krogsgaard LR; Engsbro AL; Bytzer P
Scand J Gastroenterol; 2013 May; 48(5):523-9. PubMed ID: 23506174
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom.
Palsson OS; Whitehead W; Törnblom H; Sperber AD; Simren M
Gastroenterology; 2020 Apr; 158(5):1262-1273.e3. PubMed ID: 31917991
[TBL] [Abstract][Full Text] [Related]
7. Rome III vs Rome IV criteria for irritable bowel syndrome: A comparison of clinical characteristics in a large cohort study.
Vork L; Weerts ZZRM; Mujagic Z; Kruimel JW; Hesselink MAM; Muris JWM; Keszthelyi D; Jonkers DMAE; Masclee AAM
Neurogastroenterol Motil; 2018 Feb; 30(2):. PubMed ID: 28804974
[TBL] [Abstract][Full Text] [Related]
8. Latent class analysis does not support the existence of Rome IV functional bowel disorders as discrete entities.
Black CJ; Houghton LA; Ford AC
Neurogastroenterol Motil; 2022 Nov; 34(11):e14391. PubMed ID: 35531932
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and impact of self-reported irritable bowel symptoms in the general population.
Van den Houte K; Carbone F; Pannemans J; Corsetti M; Fischler B; Piessevaux H; Tack J
United European Gastroenterol J; 2019 Mar; 7(2):307-315. PubMed ID: 31080615
[TBL] [Abstract][Full Text] [Related]
10. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden.
Heidelbaugh JJ; Stelwagon M; Miller SA; Shea EP; Chey WD
Am J Gastroenterol; 2015 Apr; 110(4):580-7. PubMed ID: 25781368
[TBL] [Abstract][Full Text] [Related]
11. Factor Analysis Defines Distinct Upper and Lower Gastrointestinal Symptom Groups Compatible With Rome IV Criteria in a Population-based Study.
Clevers E; Whitehead WE; Palsson OS; Sperber AD; Törnblom H; Van Oudenhove L; Tack J; Simrén M
Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1252-1259.e5. PubMed ID: 29510215
[TBL] [Abstract][Full Text] [Related]
12. The epidemiology of irritable bowel syndrome: Symptom development over a 3-year period in Denmark. A prospective, population-based cohort study.
Krogsgaard LR; Engsbro AL; Jones MP; Bytzer P
Neurogastroenterol Motil; 2017 Apr; 29(4):. PubMed ID: 27865035
[TBL] [Abstract][Full Text] [Related]
13. Examination of competing diagnostic models of functional gastrointestinal disorders related to pain in children.
Schurman JV; Karazsia BT; Friesen CA
Neurogastroenterol Motil; 2017 Nov; 29(11):. PubMed ID: 28656703
[TBL] [Abstract][Full Text] [Related]
14. Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome.
Barberio B; Houghton LA; Yiannakou Y; Savarino EV; Black CJ; Ford AC
Am J Gastroenterol; 2021 Feb; 116(2):362-371. PubMed ID: 33009062
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study.
Aziz I; Palsson OS; Törnblom H; Sperber AD; Whitehead WE; Simrén M
Lancet Gastroenterol Hepatol; 2018 Apr; 3(4):252-262. PubMed ID: 29396034
[TBL] [Abstract][Full Text] [Related]
16. Societal costs for irritable bowel syndrome--a population based study.
Hillilä MT; Färkkilä NJ; Färkkilä MA
Scand J Gastroenterol; 2010 May; 45(5):582-91. PubMed ID: 20166844
[TBL] [Abstract][Full Text] [Related]
17. How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors.
Aziz I; Törnblom H; Palsson OS; Whitehead WE; Simrén M
Am J Gastroenterol; 2018 Jul; 113(7):1017-1025. PubMed ID: 29880963
[TBL] [Abstract][Full Text] [Related]
18. Cumulative Effect of Psychological Alterations on Gastrointestinal Symptom Severity in Irritable Bowel Syndrome.
Midenfjord I; Borg A; Törnblom H; Simrén M
Am J Gastroenterol; 2021 Apr; 116(4):769-779. PubMed ID: 33982947
[TBL] [Abstract][Full Text] [Related]
19. Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III.
Ersryd A; Posserud I; Abrahamsson H; Simrén M
Aliment Pharmacol Ther; 2007 Sep; 26(6):953-61. PubMed ID: 17767480
[TBL] [Abstract][Full Text] [Related]
20. [A comparison between Rome III and Rome II criteria in diagnosing irritable bowel syndrome].
Wang AJ; Liao XH; Hu PJ; Liu SC; Xiong LS; Chen MH
Zhonghua Nei Ke Za Zhi; 2007 Aug; 46(8):644-7. PubMed ID: 17967234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
